Landfar(SZ:000504) Zhi Tong Cai Jing·2025-08-11 14:42Core Viewpoint - The company *ST Bio is planning to acquire a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. for cash, which will make Huize a subsidiary and included in the consolidated financial statements. This transaction is expected to constitute a major asset restructuring as defined by regulations [1] Group 1: Company Overview - Huize Biomedical is a professional CRO company focused on drug research and clinical evaluation, offering services such as pharmaceutical research, clinical trials, and data management statistical analysis [1] - Prior to the acquisition, the company primarily engaged in two business segments: "biomedical" and "energy conservation and environmental protection," along with the production and sales of related biomedical products [1] Group 2: Strategic Intent - The acquisition aims to extend the company's biomedical business, enhancing its profitability and risk resistance [1] - There is a strong correlation between cell clinical transformation research and drug development, and the asset integration is expected to improve operational efficiency and create significant synergies [1]